Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Determines Other FAAH Inhibitors are Safe to Test

By Ryan Bushey | August 16, 2016

The Food and Drug Administration announced a completion of a comprehensive safety review that focused on the fatty acid amide hydrolase (FAAH) inhibitor drug used in the deadly clinical trial that occurred in France earlier this year.

Information obtained from the European Medicines Agency and the French National Medicines Agency helped the FDA decide that the candidate used in the trial hosted by French CRO Biotrial on behalf of Portuguese pharmaceutical firm Bial exhibited “a unique toxicity that does not extend to other drugs in the class,” according to the agency’s official statement.

Currently, there are no clinical trials related to FAAH inhibitors scheduled to occur in the U.S. this year. However, the FDA pledged to work with sponsors to lay the foundation for appropriate testing for FAAH inhibitors in the U.S. along with ensuring all parties linked to these clinical trials are well aware of the benefits and risks.

Previous test trials of FAAH inhibitors didn’t raise safety concerns in the past, but the trial in France raised concerns when it was reported six participants had taken a higher dose of the drug, reported FierceBiotech.  All six volunteers were rushed to the hospital where one fell into a coma before passing away while the others remained hospitalized and later recovered.  

Some reports of Biotrial and Bial had criticized the way the companies helped these patients after giving them a high dose of the drug and shared information with authorities in the aftermath of this event.   


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE